QUÉBEC CITY, June 13,
2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company") today announced that
Brian H. Kushner, MD, of the
Memorial Sloan-Kettering Cancer Center in New York, will be making a poster presentation
on Phase 1 results for perifosine in neuroblastoma, at the Advances
in Neuroblastoma Research Conference which will be held
June 18-21, 2012, at the Fairmount
Royal York Hotel in Toronto.
| Poster #POC27: |
"Targeting PI3K/Akt Pathway: Perifosine Monotherapy for
Resistant Neuroblastoma in a Phase 1/1B Study", B. Kushner, N-K.V.
Cheung, S. Modak, O. Becher, E.M. Basu, S.S. Roberts, K.
Kramer, I.J. Dunkel. |
| |
|
| Date and time: |
Wed., June 20, 2012, 12:30 pm - 2:30 pm + 5:30 pm -
6:30 pm (Eastern) |
| |
|
| Venue: |
Royal Canadian Ballroom, Fairmount Royal York Hotel,
Toronto |
| |
|
About Perifosine
Perifosine is a novel, oral PI3K/Akt inhibitor
compound. It is currently in a Phase 3 trial in multiple myeloma
for which it has been granted orphan drug and Fast Track
designations by the Food and Drug Administration (FDA), as well as
positive Scientific Advice and orphan medicinal product designation
from the European Medicines Agency. It has also been granted orphan
drug designation by the FDA for neuroblastoma. Furthermore,
perifosine is in earlier-stage development for other cancer
indications.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and
endocrinology drug development company currently investigating
treatments for various unmet medical needs. The Company's pipeline
encompasses compounds at all stages of development, from drug
discovery through to marketed products. For more information please
visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.